Billionaire Joe Lonsdale’s 8VC Backs Plan to Breed 30,000 Lab Monkeys in the US

Joe Lonsdale, the Palantir co-founder and venture investor, is backing one of the most contentious ventures in American biotechnology. His firm, 8VC, has invested $20 million in Safer Human Medicine, a startup that plans to breed about 30,000 macaque monkeys for drug safety testing and biomedical research. The company has raised $28 million in total.

Lonsdale has framed the investment as a matter of national resilience. “America needs a reliable domestic supply of research primates to help rapidly advance cures for our kids,” he said. Jim Harkness, the company’s founder and chief executive, describes the animals in supply-chain terms: “We refer to primates as the rare earth minerals of biotech.”

The commercial logic rests on a genuine shortage. But the venture faces two obstacles that its investors cannot easily control. Its flagship facility in Georgia remains tied up in litigation and local opposition. And US regulators are actively reducing the types of primate studies that have historically driven demand. For executives and investors, Safer Human Medicine is a case study in how supply-chain scarcity, regulatory change and ethical controversy can intersect in a single business.

A supply shock in drug development

Non-human primates, mainly macaques, are used in safety studies for many drugs, particularly biologics such as monoclonal antibodies, whose effects in rodents often do not reflect their effects in humans. For decades, US laboratories relied heavily on imports.

That supply has been disrupted repeatedly. China, which once provided about 60% of the monkeys used in US biomedical research, halted exports in 2020. Laboratories turned to Cambodia, where prices rose to as much as $20,000 per animal from about $3,000 a few years earlier. In late 2022, the US Justice Department charged members of an alleged smuggling ring, including Cambodian wildlife officials, with exporting wild-caught monkeys labeled as captive-bred, further constraining supply. Today, most long-tailed macaques imported into the United States come from Mauritius and Vietnam.

For drug developers, the shortage has increased costs and delayed studies. Long-duration safety studies for some monoclonal antibody programs can require more than 100 macaques, at an estimated cost of up to $50,000 per animal including study expenses. A reliable domestic supplier would reduce dependence on foreign governments, smuggling enforcement and volatile prices.

A stalled flagship site

Safer Human Medicine has made partial progress. In 2025 it acquired a facility in LaBelle, Florida, which now holds and quarantines monkeys and has customers lined up.

Its larger ambition, a breeding center in Bainbridge, Georgia, has not advanced. In December 2023, local officials approved an incentive package of up to $300 million in revenue bonds, about 200 acres of land and 10 years of property-tax relief, in exchange for a pledged $270 million investment and about 263 jobs. Residents raised concerns about noise, odor, disease and escapes, and animal-rights groups, including PETA, organized opposition. In February 2024, the county development authority withdrew from the agreement.

Litigation followed on several fronts. State courts upheld the validation of the bonds, and Georgia’s Supreme Court declined to review that decision in April 2025. Separate disputes over open-meetings compliance, a nuisance claim by residents and the company’s federal lawsuit to enforce its project agreement have continued. The company does not yet own the Georgia land, and the facility is not operating.

The regulatory headwind

The more significant long-term risk may come from Washington. In December 2022, Congress removed the long-standing requirement that new drugs be tested on animals before human trials, allowing alternatives such as computer modeling, lab-grown tissues and organ-on-a-chip systems.

The FDA has since moved further. In April 2025, it published a roadmap to reduce animal testing in preclinical safety studies, starting with monoclonal antibodies, one of the largest categories of primate use. In December 2025, it issued draft guidance setting out when six-month primate toxicity studies for certain antibody programs could be reduced or eliminated. In April 2026, it reported meeting its first-year goals, including broader acceptance of new approach methodologies across more safety endpoints. The agency argues that animal studies are poor predictors of human outcomes, noting that about 90% of drugs that pass animal testing still fail in humans.

That trajectory creates an awkward question for Safer Human Medicine’s investors. A breeding operation of 30,000 animals takes years to build and is designed to serve demand over decades. If regulators continue to reduce primate testing requirements, the shortage the company is responding to could ease from the demand side before its capacity comes online.

Scientists caution that alternatives cannot yet replace animal studies for many complex drugs. “Cutting corners on safety and efficacy assessments is never going to be a good thing to do for society,” said Kenneth Ramos, a professor of medical sciences at Texas A&M University. Demand for primates is therefore unlikely to disappear, but its future scale is uncertain.

The ethical and reputational dimension

Primate research remains one of the most contested areas of biomedical science. Opponents argue that breeding tens of thousands of intelligent, social animals for experimentation is unjustifiable, particularly as alternatives improve. Lonsdale has described the venture as “pro-human,” arguing that the medical benefits outweigh the costs, and has asked: “Would you rather save your sibling or the monkey?”

The company also faces questions about its leadership’s history. Harkness was previously chief operating officer of Envigo, a research-animal supplier whose Virginia beagle-breeding facility was shut down in 2022 after federal inspectors documented serious welfare violations. Envigo’s parent company, Inotiv, later pleaded guilty and paid a record $35 million in fines and settlements. Harkness left Envigo in 2022 and was never charged; he has declined to comment on the matter. Opponents of the Georgia facility have cited that history, which raises the reputational stakes for any operational failure.

Why this matters for business leaders

For pharmaceutical and biotech companies, primate supply remains a strategic vulnerability. Diversifying suppliers, investing in alternative testing methods and engaging early with regulators on non-animal approaches can reduce exposure to price spikes and delays.

For investors, Safer Human Medicine illustrates the risk of building long-lived capacity against a market that regulators are deliberately reshaping. Scarcity can justify investment, but only if demand persists long enough to earn a return.

For boards, the venture shows how ethical controversy translates into commercial risk: local incentives can be withdrawn, litigation can stall projects, and leadership histories can become central to public debate.

Executive Takeaways

What changed: Joe Lonsdale’s 8VC has emerged as the main investor in Safer Human Medicine, which plans to breed about 30,000 macaques in the United States.

Why it matters: The venture addresses a real shortage of research primates, but faces legal obstacles in Georgia and a regulatory shift that may reduce long-term demand.

What leaders should do next: Drug developers should reduce dependence on primate supply through alternative methods and supplier diversification, while investors should weigh regulatory trajectory as heavily as current scarcity.

Over the next 12 to 24 months, the indicators to watch are the outcome of the Georgia litigation, the expansion of the Florida facility, the finalization of the FDA’s guidance on primate studies for monoclonal antibodies, and trends in macaque import prices. The principal uncertainty is the pace of regulatory change. If alternatives to animal testing mature quickly, the shortage Lonsdale is backing may prove temporary. If they do not, a domestic supplier could become critical biomedical infrastructure.

Have you read?
Vanuatu Citizenship-by-Investment Program. Best Golden Visa and Residency-by-Investment Programs in the World.
Australia National Innovation Visa Program. Austria Private Residence Program. Bulgaria Residency-by-Investment Program.

Follow CEOWORLD Magazine on: Google News, LinkedIn, X (Twitter), and Facebook.

Note: The views expressed are those of the authors and do not necessarily reflect those of CEOWORLD Magazine, its Editorial Board, or management. Content is provided "as is," may contain monetized links, and is not professional advice. See our Ethics & Guidelines for details. Reproduction requires prior written permission.

Contact info@ceoworld.biz for inquiries or media requests.